Pastorino U, et al. Blood microRNA and LDCT reduce unnecessary LDCT repeats in lung cancer screening: results of prospective BioMILD trial. Abstract PL02.04. WCLC 2019, 7-10 september, Barcelona, Spanje.
Vierwekelijks subcutaan amivantamab plus lazertinib leidt tot hoge respons
jan 2026 | Longoncologie